Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has shared an announcement.
Faron Pharmaceuticals Ltd has issued a correction to its previously published 2025 Annual Report after discovering that the original version omitted the auditor’s report. The company has now released an updated Annual Report including the full auditor’s report, with English and Finnish versions of the financial documents made available as PDF files on its website, improving disclosure completeness for investors and other stakeholders.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies that harness the patient’s own immune system. Its lead asset, bexmarilimab, is an investigational Clever-1–targeting therapy being evaluated in multiple trials for hematological malignancies and solid tumors, including the BEXMAB Phase I/II study in AML and MDS.
Find detailed analytics on FARN stock on TipRanks’ Stock Analysis page.